MLTX INVESTOR ALERT: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

Core Viewpoint - The MoonLake class action lawsuit alleges that MoonLake Immunotherapeutics and certain executives violated the Securities Exchange Act of 1934, impacting investors who purchased or acquired its common stock [1][3]. Group 1: Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases, with its sole drug candidate being sonelokimab (SLK) aimed at treating hidradenitis suppurativa (HS) [3][4]. - The commercial prospects of SLK were contingent on demonstrating efficacy comparable or superior to Union Chimique Belge's BIMZELX, an FDA-approved monoclonal antibody for HS [3]. Group 2: Allegations and Impact - The lawsuit claims that during the class period, MoonLake made false or misleading statements regarding SLK's clinical benefits, including its molecular targets and tissue penetration capabilities [4]. - On September 28, 2025, MoonLake announced that SLK failed to show competitive efficacy compared to BIMZELX in its Phase 3 VELA program, leading to a nearly 90% drop in the stock price [5].